Hansa Biopharma partners with Cradle on AI-driven protein design platform

Bitget2026/10/01 06:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hansa Biopharma entered a collaboration with Cradle to deploy an AI protein-design platform across its R&D programs.
Partnership targets faster design, optimization, development of new immunomodulatory drug candidates for severe autoimmune diseases.
Cradle platform supports hit identification, multi-parameter optimization, active learning from Hansa data to improve predictability in lab-in-the-loop workflows.
Hansa flagged Cradle customer results of up to 18 months shorter development timelines, implying potential R&D savings per candidate.
Deal aligns with Hansa’s strategy to expand AI-driven drug development while advancing its IgG-cleaving enzyme pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202610010200BITN____UKPR__SV_20260930-BIT-7567-0) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hansa Biopharma partners with Cradle on AI-driven protein design platform

You may also like

Crypto prices